Abstract:Until now, there are still few comparisons between neoadjuvant immunochemotherapy and chemotherapy as first-line treatment for patients with stage IB-IIIB lung squamous cell carcinoma (LUSC). In addition, the ability of pathologic response to predict long-term survival has still not been established. In this retrospective, controlled clinical trial, we ultimately enrolled 231 patients with stage IB to IIIB LUSC who received 2–4 cycles perioperative immunochemotherapy or chemotherapy alone, followed by resection. The primary endpoint of this study was pathological response. Secondary endpoints were disease-free survival (DFS), overall survival (OS), objective response rate (ORR), surgical resection rate and adverse events (AEs). The rates of major pathologic response (MPR) and pathologic complete response (pCR) in the immunochemotherapy group were 66.7% and 41.9%, respectively, which were both higher than that in the other group (MPR: 25.0%, pCR: 20.8%) (P < 0.001). The median DFS in the chemotherapy group was 33.1 months (95% CI 8.4 to 57.8) and not reached in the immunochemotherapy group (hazard ratio [HR] for disease progression, disease recurrence, or death, 0.543; 95% CI 0.303 to 0.974; P = 0.038). The median OS of the immunochemotherapy group was not achieved (HR for death, 0.747; 95% CI 0.373 to 1.495; P = 0.41), with the chemotherapy group 64.8 months (95% CI not reached to not reached). The objective response rate (ORR) of immunochemotherapy regimen was higher than that of the chemotherapy regimen (immunochemotherapy: 74.5%, chemotherapy: 42.3%, P < 0.001). About 60.8% in the immunochemotherapy group and 61.5% in the chemotherapy group eventually underwent surgery. The incidence of grade3 and 4 adverse events was 18.3% in the immunochemotherapy group and 2.6% in the chemotherapy group. MPR was significantly associated with DFS and OS (HR, 0.325; 95% CI 0.127 to 0.833; P = 0.019; and HR, 0. 906; 95% CI 0.092 to 1.008; P = 0.051, respectively). The C-index of MPR (0.730 for DFS, 0.722 for OS) was higher than the C-index of cPR (0.672 for DFS, 0.659 for OS) and clinical response (0.426 for DFS, 0.542 for OS). Therapeutic regimen (P < 0.001; OR = 7.406; 95% CI 3.054 to 17.960) was significantly correlated with MPR. In patients with stage IB to IIIB LUSC, neoadjuvant treatment with immunochemotherapy can produce a higher percentage of patients with a MPR and longer survival than chemotherapy alone. MPR may serve as a surrogate endpoint of survival to evaluate neoadjuvant therapy.

The study of the lymphatic immunochemotherapy on gastric carcinoma

The Lymphangial Immunochemotherapy of the Advanced Gastric Carcinoma Before and after the Operation

The Relationship Between the Number of Examined Lymph Nodes and the Efficacy of Chemotherapy for Gastric Cancer

Preoperative Lymphangial Chemotherapy on Breast Carcinoma

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

The Clinical Study of Thymosinα1 Therapeutic Effect of Chemotherapy in Advanced Gastric Cancer

Efficacy of Neoadjuvant Immunochemotherapy and Survival Surrogate Analysis of Neoadjuvant Treatment in IB–IIIB Lung Squamous Cell Carcinoma

Study of Lentinan's Promotion on XELOX Regimen's Curative Effects on Advanced Gastric Cancer

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer

Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer

Lymphatic Targeting Chemotherapy for Refractory Lymph Nodes in Patients with Breast Cancer after Neoadjuvant Chemotherapy: Preliminary Experience.

Preoperative Intra-Arterial Infusion Chemotherapy and Chemiluminescence of Peripheral Blood Lymphocyte in Patients with Gastric Cancer

Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

The Effect of Immunotherapy on the Gut Microbiota, Intestinal Barrier, and Immune Function in Patients with Gastric Cancer

A clinical study of thermotherapy combined intravenous chemotherapy and intraperitoneal chemotherapy for the treatment of advanced gastrointestinal carcinoma

The study on the preparation and characterization of gene-loaded immunomagnetic albumin nanospheres and their anti-cell proliferative effect combined with magnetic fluid hyperthermia on GLC-82 cells

The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicenter Real-world clinical study

Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real‐world retrospective study

Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma.

The efficacy of the interventional treatment of advanced gastric cancer

Mechanism of gemcitabine combined with lobaplatin in interventional treatment of locally advanced cervical cancer